{
    "nct_id": "NCT03008187",
    "official_title": "A Phase I/II Study of SEL24 in Patients With Acute Myeloid Leukemia",
    "inclusion_criteria": "* patients with diagnosis of Acute Myeloid Leukemia, all comers (completed) and bearing IDH1 or IDH2 mutation (open for recruitment)\n* Patient has no standard therapeutic options available and has either Relapsed AML unsuitable for intensive chemotherapy and not eligible for any approved targeted therapy or Primary refractory AML unsuitable for intensive chemotherapy and not eligible for any approved targeted therapy\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* anti-cancer treatments (including cytotoxic chemotherapy, radiotherapy, hormonal therapy, biologic, immunotherapy or investigational drugs) received within 14 days or 5 half-lives for targeted therapies (whichever is shorter) before first dose of study drug (to be supplemented)",
    "miscellaneous_criteria": ""
}